Dr. Agarwal's Health Care Limited has delivered exceptional financial performance for Q3FY26, with consolidated net profit surging 51% year-on-year to ₹337m compared to ₹223m in the corresponding quarter last year. The healthcare services company reported consolidated revenue of ₹5.3b versus ₹4.3b in the same period last year, marking robust operational growth.

Strong Quarterly Financial Performance

The company's Q3FY26 results demonstrate strong operational efficiency and profitability improvements. EBITDA reached ₹1.4b compared to ₹1.1b in the same quarter last year, with EBITDA margins expanding to 27.17% from 26.5% year-on-year, indicating improved operational leverage and cost management.

Nine Months Performance Highlights

For the nine months ended December 31, 2025, the company demonstrated exceptional growth momentum. Total income soared by 20.8% year-on-year to INR 1,548 Cr, while revenue from operations grew by 21.2% to INR 1,516 Cr. The company's profitability showed remarkable improvement with profit after tax growing by 74.3% to INR 118 Cr.

Operational Expansion and Network Growth

As of December 31, 2025, the company's network expanded to 272 facilities, with 14 new centers added during Q3FY26 comprising 9 secondary and 5 primary facilities. During the nine months period, 38 new centers were added including 1 tertiary, 22 secondary and 15 primary facilities. The company performed 81,002 surgeries in Q3FY26, showing an 11.2% year-on-year growth, while nine months surgeries reached 238,283, representing an 11.6% increase.

Board Meeting Decisions and Corporate Actions

The Board of Directors met on February 03, 2026, to approve several significant decisions beyond the quarterly results. The board approved the incorporation of a wholly owned subsidiary in Ethiopia through Orbit Healthcare Services (Mauritius) Limited, with an investment of 200,000 USD. Additionally, the board approved shifting the registered office from Buhari Towers to 6th Floor, Menon Eternity, 1st Main Road, Austin Nagar, Alwarpet, Chennai 600 018, effective February 05, 2026.

Management Commentary

Dr. Adil Agarwal, CEO, commented on the strong performance: "The Company delivered a strong performance in Q3 FY26, marked by robust growth across revenues and profitability, reflecting sustained execution momentum. Revenue from Operations grew by 23.0% YoY to ₹530 Cr, driven by healthy patient volumes, strong traction across mature centres, and improving contribution from newer facilities."

The company remains focused on accelerating organic growth through aggressive greenfield expansion while maintaining high standards of patient safety and clinical quality. With 900+ doctors serving over 22 lakh patients during the nine months period, the company continues to strengthen its position as India's largest eye care service chain by revenue.

Dr. Agarwal's Health Care Limited has completed the allotment of 3,37,504 equity shares to eligible employees under its Employee Stock Option Scheme 2022. The allotment, approved by the Nomination and Remuneration Committee through a circular resolution dated January 06, 2026, represents the latest exercise of vested stock options by company employees.

Latest ESOP Allotment Details

The recent share allotment was executed at a uniform exercise price, demonstrating the company's continued commitment to employee participation:

The shares have been allotted under the Dr. Agarwal's Health Care Limited - Employee Stock Option Scheme 2022. All allotted equity shares rank pari passu with the existing equity shares of the company, ensuring equal rights and privileges for the holders.

Updated Share Capital Structure

The latest ESOP exercise has resulted in a significant increase in the company's paid-up equity share capital:

The distinctive number range for the newly allotted shares spans from 31,64,70,003 to 31,68,07,506, with the ISIN code INE943P01029 applicable for demat issuance.

Regulatory Compliance and Documentation

The allotment has been conducted in full compliance with Regulation 10(c) of the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The company filed the required statement under regulation 10(b) with the recognized stock exchanges on February 24, 2025, receiving filing numbers BSE-224564 and NSE-NSE/LIST/47322.

Company Information

Dr. Agarwal's Health Care Limited operates in the healthcare sector and maintains its registered office at 1st Floor, Buhari Towers, No. 4, Moore's Road, Off Greams Road, Near Asan Memorial School, Chennai-600006. The company's shares are listed on both BSE Limited (Scrip Code: 544350) and National Stock Exchange of India Limited (Symbol: AGARWALEYE), providing liquidity and accessibility to investors across major Indian stock exchanges.